BTIG’s Tim Chiang still spots challenges in VRX’s orbit, but likewise pinpoints strength in eyecare business Bausch + Lomb, which boasts robust international gains.
Ken Griffin is a man known to be raring to take a risk when it is worthwhile, a daring and strategic mindset that …
One of the world’s top fund managers is backing volatile healthcare stocks VRX and MNKD.
Deutsche Bank’s Gregg Gilbert is concerned about the unpredictability of VRX’s legal hurdles that lie ahead.
Israel “Izzy” Englander isn’t afraid to go against the market on TEVA, VRX and ACAD.
BMO stays on the sidelines as VRX still faces headwinds, but praises key “headway” in growth.
Though investor sentiment has turned positive on VRX after 3Q earnings, Wells Fargo makes a bearish case.
Ram Selvaraju needs to see more proof of VRX’s pipeline staying power and ability to yield gains.
BTIG’s Tim Chiang believes a lot hinges on the Vyzulta launch for VRX to stage a solid comeback.
It’s a win for the bulls as VRX’s execution and robust growth down the line bode well for the giant’s future.
